Randomized comparison of vaginal and sublingual misoprostol with mifepristone priming in termination of second trimester pregnancy
DOI:
https://doi.org/10.18203/2320-6012.ijrms20194323Keywords:
Mifepristone, Misoprostol, Second Trimester, Sublingual, VaginalAbstract
Background: Sublingual Misoprostol 200 ug 4 hrly is as effective or less effective than vaginal Misoprostol 200ug 4hrly with 200mg oral Mifepristone in termination of second trimester pregnancy.
To compare effectiveness, side-effects, and patient satisfaction of sublingual vs vaginal misoprostol administration.
Methods: It was prospective randomized open label study. 60 women 13-20 weeks of gestation with a valid legal indication for termination of pregnancy as per MTP act in INDIA were enrolled for study, randomly divided into Group A- Sublingual (n=30) group B-Vaginal (n=30). For group A, 200 mg of Mifepristone was given, 48h later Misoprostol 200 µg was given sublingually 4hrly up to a maximum of 5 doses. If abortion does not occur, the pregnancy was terminated with vaginal misoprostol, in group A. Same procedure repeated in group B. If abortion fails to occur after 5 doses, then second course of vaginal misoprostol was given in group B. Failure of procedure was defined as failed expulsion of foetus at 48 hrs.
Results: Mean induction-abortion interval in vaginal group was 12.8±4.38h and 11.47±4.42h in sublingual group was comparable with insignificant p value (p=0.136). All the side effects were comparable in both groups. The overall success rate was 93.3% in the sublingual group while it was 100% in the vaginal group.
Conclusion: Vaginal misoprostol with oral mifepristone priming in second -trimester medical abortion has a shorter time to pregnancy termination compared with a sublingual regimen. However, both the routes are equally effective for induction of abortion.
References
Dhillon BS, Chandhiok N, Kambo I, Saxena NC. Induced abortion and concurrent adoption of contraception in the rural areas of India (an ICMR task force study). Indian J Med Sci. 2004;58:478-84.
Sedgh G, Henshaw S, Singh S, Ahman E, Shah IH. Induced abortion: Estimated rates and trends worldwide. The Lancet. 2007 Oct 13;370(9595):1338-45.
Padubidri VG, Daftary SN. Shaw’s textbook of gynaecology (13th ed), New Delhi, Elsevier. 2004:241.
Tejal P, Bakul A. 17-year review of voluntary termination of pregnancy (MTP). J Obstetr Gynecol India. 2006;56(6):522-8.
Tejal P, Bakul L. A 17-year review of voluntary termination of pregnancy (MTP). J Obstetr Gynecol India. 2006;56(6);522-8.
World Health Organization. Medical methods for termination of pregnancy, World Health Organization, Geneva 1997,871. Available at: extranet.who.int.
Cabrera Y, Fernández‐Guisasola J, Lobo P, Gamir S, Alvarez J. Comparison of sublingual versus vaginal misoprostol for second trimester pregnancy termination, A meta-analysis. Aust N Z Y Obstet-Gynecol. 2011;51(2),158-65.
Darney PD, Sweet RL. Routine intraoperative ultrasonography for second trimester abortion reduces incidence of uterine perforation. J Ultrasound Med. 1989;8(2):71-5.
Ngai SW, Tang OS, Chan YM, Ho PC. Vaginal misoprostol alone for medical abortion up to 9 weeks of gestation: efficacy and acceptability. Human Reproduct. 2000 May 1;15(5):1159-62.
Tang OS, Ho PC. Pilot study on the use of sublingual misoprostol for medical abortion. Contraception. 2001;64(5):315-7.
Autry AM, Hayes EC, Jacobson GF, Kirby RS. A comparison of medical induction and dilation and evacuation for second-trimester abortion. Am J Obstet Gynecol. 2002;187(2):393-7.
Bartley J, Baird DT. A randomised study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy. BJOG 2002;109(11):1290-4.
Ashok PW, Templeton A, Wagaarachchi PT, Flett GM. Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases. Contracept. 2004;69(1):51-8
Urquhart DR, Bahzad C, Templeton AA. Efficacy of the antiprogestin mifepristone (RU 486) prior to prostaglandin termination of pregnancy. Human Reproduct. 1989 Feb 1;4(2):202-3.
Urquhart DR, Templeton AA. The use of mifepristone prior to prostaglandin-induced mid-trimester abortion. Human Reproduct. 1990 Oct 1;5(7):883-6.
Tanha FD, Golgachi T, Niroomand N, Ghajarzadeh M, Nasr R. Sublingual versus vaginal misoprostol for second trimester termination: a randomized clinical trial. Archiv Gynecolo Obstetr. 2013 Jan 1;287(1):65-9.
Tanha FD, Golgachi T, Niroomand N, Gajaradeh M, Nasr R. Sublingual versus vaginal misoprostol for second trimester termination; a randomized clinical trial. Arch Gynecol obstet. 2013;287(1);659.
Fogsi Icog Good Clinical Practice Recommendation Medical Termination of Pregnancy: J Obstetr Gynecol of India. 2011;91.
World Health Organisation; Safe abortion: Technical and Policy guidance for health systems 2nd ed. Geneva: 2012. Available at: apps.who.int.
Wildschut H, Both MI, Medema S, Thomee E, Wildhagen MF, Kapp N. Medical methods for Mid-trimester termination of pregnancy. Cochrane Database Syst Rev. 2011;19(1):CD005216.
Dickinson JE, Brownell P, McGinnis K, Nathan E. Mifepristone and second trimester pregnancy termination for fetal abnormality in Western Australia: worth the effort. Aust NZ J Obstet Gynaecol. 2010;50(1):60-4.
Milani F, Sharami SH, Arjmandi S. Comparison of sublingual and vaginal misoprostol for second-trimester pregnancy terminations. J Family Reprod Health. 2014 Mar;8(1):41-4.
Bartusevicius A, Barcaite E, Nadisauskiene R. Oral, vaginal and sublingual misoprostol for induction of labor. Int J of Gynecol Obstet. 2005; 91:2-9.
el-Refaey H, Templeton A. Induction of abortion in the second trimester by a combination of misoprostol and mifepristone: a randomized comparison between two misoprostol regimens. Hum Reprod. 1995;10(2):475-8.
Ashok PW, Templeton A. Nonsurgical mid‐trimester termination of pregnancy: a review of 500 consecutive cases. BJOG: Intern J Obst Gynaecol. 1999 Jul;106(7):706-10.
Ashok PW, Templeton A, Wagaarachchi PT, Flett GM. Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases. Contracept. 2004 Jan 1;69(1):51-8.
Dickinson JE, Brownell P, McGinnis K, Nathan E. Mifepristone and second trimester pregnancy termination for fetal abnormality in Western Australia: worth the effort. Aust NZ J Obstet Gynaecol. 2010;50(1):60-4.
Tang OS, Chan CC, Ng EH, Lee SW, Ho PC. A prospective, randomized, placebo‐controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. Human Reprod. 2003 Nov 1;18(11):2315-8.
Hamoda H, Ashok PW, Dow J, Flett GM, Templeton A. A pilot study of mifepristone in combination with sublingual or vaginal misoprostol for medical termination of pregnancy up to 63 days gestation. Contracept. 2003;68(5):335-8.
Tang OS, Schweer H, Seyberth HW, Lee SW, Ho PC. Pharmacokinetics of different routes of administration of misoprostol. Human Reproduc. 2002;17(2):332-6.
Tang OS, Lau WN, Chan CC, Ho PC. A prospective randomised comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy. BJOG. 2004;111(9),1001-05.